Celecoxib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Celecoxib
- Celecoxib: From Arthritis and Pain Management to Acromesomelic Dysplasia, Hunter-Thompson Type
Celecoxib: From Arthritis and Pain Management to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Celecoxib is a COX-2 selective NSAID, used mainly for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute pain. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction is model-only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the US license data provided. Published reviews describe osteoarthritis, rheumatoid arthritis, juvenile arthritis, ankylosing spondylitis and acute pain |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the listed records are ANDAs, i.e. generics) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. From general knowledge, celecoxib selectively inhibits COX-2 and reduces prostaglandin-mediated inflammation and pain.
The predicted disease is a monogenic skeletal dysplasia caused by loss of function in CDMP1/GDF5, which impairs limb growth. COX-2 inhibition does not act on this genetic or developmental defect, so no credible mechanistic link was found.
The very high TxGNN score (99.88%) most likely reflects proximity to musculoskeletal terms in the knowledge graph, not a pharmacological rationale. It should be treated as a model artifact unless independent evidence appears.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA205129 | Celecoxib (Radha Pharmaceuticals) | Capsule | Not provided in source data |
| ANDA204776 | Celecoxib (Northwind Health Company) | Capsule | Not provided in source data |
| ANDA204519 | Celecoxib (Alembic Pharmaceuticals) | Capsule | Not provided in source data |
| ANDA206827 | Celecoxib (Vangard Labs) | Capsule | Not provided in source data |
| ANDA204590 | Celecoxib (RedPharm Drug) | Capsule | Not provided in source data |
All listed products are oral capsules (5 of 20 licenses shown).
Other Predicted Candidates (Same Drug)
The evidence pack contains 10 predictions. Only two others have any supporting data.
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Assessment |
|---|---|---|---|---|
| 2 | Brachyolmia-amelogenesis imperfecta syndrome | 99.86% | L5 | No credible link, likely a knowledge-graph artifact |
| 3 | Rheumatoid vasculitis | 99.85% | L4 | Weak, indirect link. Only one case report, and NSAIDs are not disease-modifying here |
| 4 | Myosclerosis | 99.85% | L5 | No credible disease-modifying link |
| 5 | Hypermobility of coccyx | 99.83% | L5 | Nonspecific analgesia only, no celecoxib-specific data |
| 6 | Brachyolmia | 99.83% | L5 | No credible link |
| 7 | Rheumatoid nodulosis | 99.83% | L5 | Indirect at best |
| 8 | RF-positive polyarticular juvenile idiopathic arthritis | 99.82% | L3 | Plausible. The single publication is a Phase 4 registry of safety vs nonselective NSAIDs (PMID 25057265) |
| 9 | Inflammatory spondylopathy (ankylosing spondylitis / axial spondyloarthritis) | 99.80% | L1 | Strongest signal. Details below |
| 10 | WHIM syndrome | 99.80% | L5 | No credible link (CXCR4 gain-of-function) |
Rank 9: Inflammatory Spondylopathy (Strongest Candidate)
COX-2 inhibition reduces prostaglandin E2-driven inflammation and pain, and NSAIDs are first-line therapy in guidelines. This is closer to indication confirmation or expansion than true repurposing. Evidence Level L1 is supported by two completed Phase 3 trials. The pack recommends Proceed with Guardrails.
| Trial | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00648141 | Phase 3 | Completed | 458 | 12-week comparison of celecoxib 200 mg QD, 200 mg BID and diclofenac in ankylosing spondylitis |
| NCT00762463 | Phase 3 | Completed | 240 | Celecoxib vs diclofenac SR in Chinese ankylosing spondylitis patients, with 6-week extension |
| NCT02528201 | Phase 4 | Completed | 330 | Two celecoxib doses vs diclofenac over 12 weeks in ankylosing spondylitis |
| NCT02758782 | Phase 4 | Completed | 156 | Celecoxib added to golimumab vs golimumab alone on 2-year spinal structural progression (CONSUL) |
| NCT01934933 | Phase 4 | Completed | 150 | Etanercept and celecoxib alone or combined in active ankylosing spondylitis |
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16960941 | 2006 | RCT | J Rheumatol | Celecoxib efficacious and well tolerated for signs and symptoms of ankylosing spondylitis |
| 40911151 | 2025 | Umbrella review | Drugs | Synthesis of celecoxib safety evidence in chronic musculoskeletal conditions |
| 38228361 | 2024 | RCT analysis (CONSUL) | Ann Rheum Dis | Effect of adding celecoxib to TNF inhibitor on 2-year radiographic spinal progression |
| 40028763 | 2025 | Cohort | Scand J Rheumatol | Cardiovascular and GI bleeding risk comparable between celecoxib and nonselective NSAIDs in AS |
| 39757202 | 2025 | Cohort | BMB Rep | Celecoxib reported as the only NSAID inhibiting bone progression in spondyloarthritis |
Several publications suggest celecoxib may slow radiographic or bone progression. This remains hypothesis-level. The US label may not include ankylosing spondylitis, so regional label verification is needed.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold (for the lead prediction, acromesomelic dysplasia, Hunter-Thompson type)
Rationale: The lead prediction has no trials, no literature and no plausible mechanism. The high score looks like a knowledge-graph artifact. The only candidate worth advancing is inflammatory spondylopathy (rank 9), which has two completed Phase 3 trials and is better handled as indication confirmation than repurposing.
To proceed, the following is needed:
- For the lead prediction: a mechanistic rationale linking COX-2 inhibition to GDF5/CDMP1 pathways. Without one, deprioritize it.
- For rank 9: verify the US label for ankylosing spondylitis, and assess cardiovascular and GI risk at the lowest effective dose.
- Package insert warnings and contraindications, which are missing from the pack and block safety screening.
- Detailed mechanism of action data from DrugBank.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.